OptimizeRx Q4 net income $5.0M, record adj EBITDA $12.0M; guides FY2026 rev $109-114M

OptimizeRx Corp

Q4 revenue $32.2M (flat YoY); FY2025 revenue $109.4M (+19% YoY).
Q4 GAAP net income $5.0M ($0.26/diluted share) vs net loss $0.1M in Q4 2024.
Q4 adjusted EBITDA record $12.0M; FY2025 adj EBITDA $24.3M.
FY2026 guidance: revenue $109-114M, adjusted EBITDA $21-25M.
Board authorizes $10M share repurchase program effective Mar 12, 2026 through Mar 15, 2027.

item 1.01 item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OptimizeRx Corp amended Amendment No. 4 (effective 2026-03-02).

Action: amendment
Agreement: credit facility
Effective: 2026-03-02

Exact text from the filing

On March 2, 2026, OptimizeRx Corporation (the “Company”) entered into Amendment No. 4 to the Financing Agreement (the “Amendment No. 4”).

View on SEC.gov

336 material agreements filed in the last 30 days. Browse all material agreements →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001448431-26-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.